XML 41 R44.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

License and Collaboration Agreements - Additional Information (Details) |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Apr. 30, 2019 USD ($) shares | Oct. 31, 2017 USD ($) | Sep. 30, 2017 USD ($) Program | Aug. 31, 2017 USD ($) | Dec. 31, 2019 USD ($) shares | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($)
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Revenue recognized |  |  |  |  | $ 7,000,000 |  |
Deferred revenue, current |  |  |  |  | 7,000,000 | $ 6,250,000 |
Deferred revenue, noncurrent |  |  |  |  | 12,022,000 | 16,984,000 |
Research and development |  |  |  |  | $ 78,481,000 | 49,646,000 |
Shares probable of vesting | shares |  |  |  |  | 4,738,004 |  |
Taiho Pharmaceutical Co Ltd | Taiho Agreement |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Option period |  |  | 5 years |  |  |  |
Non refundable and non creditable cash payments |  |  |  |  |  |  | $ 35,000,000
Payment received for license agreement |  | $ 5,000,000 |  |  | $ 5,000,000 | $ 5,000,000 | $ 25,000,000
Range of royalties receivable on net sales |  |  |  |  | high single-digits to mid-teens |  |
Royalties payable description |  |  |  |  | Royalties will be payable on a licensed product-by-licensed product and country-by-country basis during the period of time commencing on the first commercial sale of a licensed product in a country and ending upon the later of: (a) ten (10) years from the date of first commercial sale of such licensed product in such country; and (b) expiration of the last-to-expire valid claim of the Company’s patents covering the manufacture, use or sale or exploitation of such licensed product in such country (the Royalty Term) |  |
Upfront cash payment |  |  | $ 20,000,000 |  |  |  |
Non-refundable, non-creditable upfront cash payments |  |  |  |  | $ 35,000,000 |  |
Estimated performance period |  |  |  |  | 5 years | 4 years | 5 years
Payment for first option exercise |  |  |  |  | $ 8,000,000 | $ 3,000,000 |
Licensing revenue recognized |  |  |  |  | 8,000,000 |  |
Clinical and regulatory milestones achieved |  |  |  |  | 0 |  |
Sales milestone or royalty revenue recognized |  |  |  |  | 0 |  |
Revenue recognized |  |  |  |  | 15,000,000 | 8,300,000 |
Deferred revenue, current |  |  |  |  | 7,000,000 |  |
Deferred revenue, noncurrent |  |  |  |  | $ 12,000,000 |  |
Taiho Pharmaceutical Co Ltd | Taiho Agreement | Minimum |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Number of programs, IND enabling studies not initiated | Program |  |  | 5 |  |  |  |
Payment for option exercise |  |  | $ 3,000,000 |  |  |  |
Taiho Pharmaceutical Co Ltd | Taiho Agreement | Maximum |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Extended option agreement period |  |  | 7 years |  |  |  |
Payment for option exercise |  |  | $ 15,000,000 |  |  |  |
Additional clinical and regulatory milestone payments receivable |  |  | 130,000,000 |  |  |  |
Contingent payments receivable |  |  | $ 145,000,000 |  |  |  |
WuXi Biologics License Agreement |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Range of tiered royalty payments on net sales |  |  |  |  | high single-digits to low teens |  |
WuXi Biologics License Agreement | Research and Development Expenses |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Milestone payments |  |  |  |  | $ 7,500,000 | 0 |
Sub-license fees |  |  |  |  | 1,200,000 |  |
WuXi Biologics License Agreement | Maximum |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Clinical, regulatory and commercialization milestone payments |  |  |  | $ 375,000,000 |  |  |
Abmuno License Agreement |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Milestone payments |  |  |  |  | 0 |  |
Abmuno License Agreement | Research and Development Expenses |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | $ 2,800,000 |
Abmuno License Agreement | Maximum |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Clinical, regulatory and commercialization remaining milestone payments |  |  |  |  | 101,000,000 |  |
Genentech |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Research and development |  |  |  |  | 0 |  |
Strata Oncology Inc | Co-Development and Collaboration Agreement |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Development milestone payable | $ 2,500,000 |  |  |  |  |  |
Development cost recorded within research and development expenses |  |  |  |  | 1,000,000 |  |
Development cost reimbursed |  |  |  |  | $ 200,000 |  |
Number of restricted shares of common stock issued | shares | 1,257,651 |  |  |  |  |  |
Fair value of restricted shares of common stock issued | $ 15,000,000 |  |  |  |  |  |
Strata Oncology Inc | Co-Development and Collaboration Agreement | Non-vested Restricted Stock |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Shares probable of vesting | shares |  |  |  |  | 0 |  |
Compensation expense recognized |  |  |  |  | $ 0 |  |
Strata Oncology Inc | Co-Development and Collaboration Agreement | Research and Development Expenses |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Milestone payments |  |  |  |  | $ 2,500,000 |  |
Strata Oncology Inc | Co-Development and Collaboration Agreement | Maximum |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |
Regulatory and commercial milestone payable | $ 125,000,000 |  |  |  |  |  |

X
- Definition Additional clinical and milestone payments received under license agreement. + References No definition available. + Details
Name: | rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Clinical and regulatory milestones achieved under license agreement. + References No definition available. + Details
Name: | rcus_ClinicalAndRegulatoryMilestonesAchievedUnderLicenseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Clinical regulatory and commercialization milestone payments. + References No definition available. + Details
Name: | rcus_ClinicalRegulatoryAndCommercializationMilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Clinical regulatory and commercialization remaining milestone payments. + References No definition available. + Details
Name: | rcus_ClinicalRegulatoryAndCommercializationRemainingMilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent milestone payments receivable. + References No definition available. + Details
Name: | rcus_ContingentMilestonePaymentsReceivable
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development milestone payable. + References No definition available. + Details
Name: | rcus_DevelopmentMilestonePayable
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Estimated performance period of agreement. + References No definition available. + Details
Name: | rcus_EstimatedPerformancePeriodOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Extended option agreement period. + References No definition available. + Details
Name: | rcus_ExtendedOptionAgreementPeriod
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License and collaboration agreements. + References No definition available. + Details
Name: | rcus_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | rcus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | rcus_MilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable and non creditable cash payments. + References No definition available. + Details
Name: | rcus_NonRefundableAndNonCreditableCashPayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non refundable and non creditable upfront cash payments. + References No definition available. + Details
Name: | rcus_NonRefundableAndNonCreditableUpfrontCashPayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of programs. + References No definition available. + Details
Name: | rcus_NumberOfPrograms
Namespace Prefix: | rcus_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option period. + References No definition available. + Details
Name: | rcus_OptionPeriod
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment for first option exercise. + References No definition available. + Details
Name: | rcus_PaymentForFirstOptionExercise
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment for option exercise. + References No definition available. + Details
Name: | rcus_PaymentForOptionExercise
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment received for license agreement. + References No definition available. + Details
Name: | rcus_PaymentReceivedForLicenseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Range of royalties receivable on net sales. + References No definition available. + Details
Name: | rcus_RangeOfRoyaltiesReceivableOnNetSales
Namespace Prefix: | rcus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Range of tiered royalty payments on net sales. + References No definition available. + Details
Name: | rcus_RangeOfTieredRoyaltyPaymentsOnNetSales
Namespace Prefix: | rcus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulatory and commercial milestone payable. + References No definition available. + Details
Name: | rcus_RegulatoryAndCommercialMilestonePayable
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Reimbursement of research and development expense excluding acquired in process cost. + References No definition available. + Details
Name: | rcus_ReimbursementOfResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalties payable description. + References No definition available. + Details
Name: | rcus_RoyaltiesPayableDescription
Namespace Prefix: | rcus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales milestone and royalty revenue recognized under license agreement. + References No definition available. + Details
Name: | rcus_SalesMilestoneAndRoyaltyRevenueRecognizedUnderLicenseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sub-license fees paid. + References No definition available. + Details
Name: | rcus_SubLicenseFeesPaid
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront cash payment. + References No definition available. + Details
Name: | rcus_UpfrontCashPayment
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate value of stock related to Restricted Stock Awards issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_OptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_AbmunoLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_GenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_StrataOncologyIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_CoDevelopmentAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |